col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


55 Results       Page 1

 [1] 
Elsevier: Molecular Therapy
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―09 A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections Namei Wu, Jiachen Zhang, Yanqiong Shen, Xinghai Zhang, Jinge Zhou, Yan Wu, et al. (+5)
2 [GO] 2024―Jan―24 Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2 Kathrin Göritzer, Elisabetta Groppelli, Clemens Grünwald-Gruber, Rudolf Figl, Fengfeng Ni, Huimin Hu, et al. (+8)
3 [GO] 2024―Jan―21 Novel engineered recombinant ACE2 reduces SARS-CoV-2-induced COVID-19 without cardiotoxic side effects Federico Ávila-Moreno
4 [GO] 2024―Jan―11 Distinct roles of vaccine induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease Jingyi Yan, Chandrashekar Ravenna Bangalore, Negin Nikouyan, Sofia Appelberg, Daniela Nacimento Silva, Haidong Yao, et al. (+20)
5 [GO] 2023―Nov―16 A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion Han Feng, Linpu Yang, Hang Yang, Dongwan Cheng, Min Li, Eli Song, Tao Xu
6 [GO] 2023―Nov―04 Intracellular delivery of nuclear localization sequence peptide mitigates COVID-19 by inhibiting nuclear transport of inflammation associated transcription factors Seokwon Lee, Sang-Sun Yoon, Minhee Jo, Mingu Kang, Seungwoo Lee, Young-Jin Seo, et al. (+3)
7 [GO] 2023―Sep―09 Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants Cheng-Pu Sun, Chi-Wen Chiu, Ping-Yi Wu, Szu-I Tsung, I-Jung Lee, Chih-Wei Hu, et al. (+25)
8 [GO] 2023―Aug―30 Inhalable Nanofitin demonstrates high neutralization of SARS-CoV-2 virus via direct application in respiratory tract Sébastien Viollet, Elise Enouf, Justine Picot, Léna Noël, Simon Huet, Déborah Le Pennec, et al. (+4)
9 [GO] 2023―May―26 A non-transmissible live attenuated SARS-CoV-2 vaccine Julia M. Adler, Ricardo Martin Vidal, Anne Voß, Sandra Kunder, Mariana Nascimento, Azza Abdelgawad, et al. (+6)
10 [GO] 2023―May―03 Extracellular vesicles: A promising therapy against SARS-CoV-2 infection Yan Leyfman, Greta Gohring, Muskan Joshi, Gayathri Pramil Menon, Alexandra Van de Kieft, Tania del Rivero, et al. (+2)
11 [GO] 2023―Mar―21 Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication Daseuli Yu, Hee-Jeong Han, Jeonghye Yu, Jihye Kim, Gun-Hee Lee, Ju-Hee Yang, et al. (+5)
12 [GO] 2023―Jan―10 Mechanisms and treatment of COVID-19-associated acute kidney injury Weibin Zhou, John Cijiang He
13 [GO] 2022―Dec―27 A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 Luigi Aurisicchio, Nadia Brambilla, Marina E. Cazzaniga, Paolo Bonfanti, Stefano Milleri, Paolo A. Ascierto, et al. (+21)
14 [GO] 2022―Dec―15 SARS-CoV-2 viral protein ORF3A injures renal tubules by interacting with TRIM59 to induce STAT3 activation Hong Cai, Ya Chen, Ye Feng, Morad Asadi, Lewis Kaufman, Kyung Lee, et al. (+9)
15 [GO] 2022―Dec―12 Treatment with Quercetin inhibits SARS-CoV-2 N protein-induced acute kidney injury by blocking Smad3-dependent G1 cell cycle arrest Wenjing Wu, Wenbiao Wang, Liying Liang, Junzhe Chen, Biao Wei, Xiao-Ru Huang, et al. (+3)
16 [GO] 2022―Sep―15 Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery Ferdinando M. Milazzo, Antonio Chaves-Sanjuan, Olga Minenkova, Daniela Santapaola, Anna M. Anastasi, Gianfranco Battistuzzi, et al. (+16)
17 [GO] 2022―Sep―10 The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs Masaud Shah, Hyun Goo Woo
18 [GO] 2022―Aug―10 Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2 Matthew D.J. Dicks, Louisa M. Rose, Rebecca A. Russell, Lesley A.H. Bowman, Carl Graham, Jose M. Jimenez-Guardeño, et al. (+5)
19 [GO] 2022―Jul―31 Moving targets: COVID-19 vaccine efficacy against Omicron subvariants Maria Karolaynne da Silva, Umberto Laino Fulco, Edilson Dantas da Silva Júnior, Jonas Ivan Nobre Oliveira
20 [GO] 2022―May―07 Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen Zaid Taha, Rozanne Arulanandam, Glib Maznyi, Elena Godbout, Madalina E. Carter-Timofte, Naziia Kurmasheva, et al. (+27)
21 [GO] 2022―Apr―27 An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa Benjamin Vesin, Jodie Lopez, Amandine Noirat, Pierre Authié, Ingrid Fert, Fabien Le Chevalier, et al. (+13)
22 [GO] 2022―Apr―21 A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity Sean McCafferty, AKM Ashiqul Haque, Aster Vandierendonck, Brian Weidensee, Magalie Plovyt, Magdalena Stuchlíková, et al. (+11)
23 [GO] 2022―Mar―24 Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single cell transcriptomics Emanuel Wyler, Julia M. Adler, Kathrin Eschke, Gustavo Teixeira Alves, Stefan Peidli, Fabian Pott, et al. (+19)
24 [GO] 2022―Mar―17 Emerging infections and pandemics: The critical importance of global health equity action Nadia A. Sam-Agudu, Chandy C. John
25 [GO] 2022―Feb―19 COVID-19 mRNA vaccines: platforms and current developments Gábor Tamás Szabó, Azita Josefine Mahiny, Irena Vlatkovic
26 [GO] 2022―Feb―14 The Battle between Host and SARS-CoV-2: Innate Immunity and Viral Evasion Strategies Shilei Zhang, Lulan Wang, Genhong Cheng
27 [GO] 2022―Feb―12 Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, Anna Maria Anastasi, Gianfranco Battistuzzi, Caterina Chiapparino, et al. (+15)
28 [GO] 2022―Feb―10 Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform Chevillard C, Amen A, Besson S, Hannani D, Bally I, Dettling V, et al. (+10)
29 [GO] 2022―Feb―03 Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2 Vijayakumar Jawalagatti, Kirthika Perumalraja, Chamith Hewawaduge, Myeon Sik Yang, Ji-Young Park, Byung Kwan Oh, John Hwa Lee
30 [GO] 2022―Jan―31 Adenovirus-based vaccines - a platform for pandemic preparedness against emerging viral pathogens Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
31 [GO] 2022―Jan―14 Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors Jonas Becker, Megan Lynn Stanifer, Sarah Rebecca Leist, Bettina Stolp, Olena Maiakovska, Ande West, et al. (+9)
32 [GO] 2022―Jan―07 Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice Myeon-Sik Yang, Min-Jung Park, Junhyeong Lee, Byungkwan Oh, Kyung Won Kang, Yeonhwa Kim, et al. (+10)
33 [GO] 2022―Jan―03 A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models Giulietta Maruggi, Corey P. Mallett, Jason W. Westerbeck, Tiffany Chen, Giuseppe Lofano, Kristian Friedrich, et al. (+30)
34 [GO] 2021―Nov―11 Debulking SARS-COV-2 in saliva using angiotensin converting enzyme 2 in the chewing gum to decrease oral virus transmission and infection Henry Daniell, Smruti K. Nair, Nardana Esmaeili, Geetanjali Wakade, Naila Shahid, Prem Kumar Ganesan, et al. (+20)
35 [GO] 2021―Oct―22 Single dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection Stephen Boulton, Joanna Poutou, Nikolas T. Martin, Taha Azad, Ragunath Singaravelu, Mathieu J.F. Crupi, et al. (+26)
36 [GO] 2021―Oct―22 The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies Serdar Durdagi, Timucin Avsar, Muge Didem Orhan, Muge Serhatli, Bertan Koray Balcioglu, Hasan Umit Ozturk, et al. (+20)
37 [GO] 2021―Oct―02 The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant Changjing Cai, Yihan Liu, Shan Zeng, Hong Shen, Ying Han
38 [GO] 2021―Sep―20 COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19 Antonella Conforti, Emanuele Marra, Fabio Palombo, Giuseppe Roscilli, Micol Ravà, Valeria Fumagalli, et al. (+49)
39 [GO] 2021―Aug―06 A comprehensive analysis of the efficacy and safety of COVID-19 vaccines Changjing Cai, Yinghui Peng, Edward Shen, Qiaoqiao Huang, Yihong Chen, Ping Liu, et al. (+9)
40 [GO] 2021―May―20 Low-dose single-shot COVID-19 mRNA vaccines lie ahead Niek N. Sanders
41 [GO] 2021―May―14 A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19 Adi Idris, Alicia Davis, Aroon Supramaniam, Dhruba Acharya, Gabrielle Kelly, Yaman Tayyar, et al. (+9)
42 [GO] 2021―May―11 Plant-derived Exosomal MicroRNAs Inhibit Lung Inflammation Induced by Exosomes SARS-CoV-2 Nsp12 Yun Teng, Fangyi Xu, Xiangcheng Zhang, Jingyao Mu, Mohammed Sayed, Xin Hu, et al. (+17)
43 [GO] 2021―Apr―23 Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, et al. (+22)
44 [GO] 2021―Apr―05 A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice. Ruklanthi de Alwis, Esther S. Gan, Shiwei Chen, Yan Shan Leong, Hwee Cheng Tan, Summer L. Zhang, et al. (+26)
45 [GO] 2021―Feb―10 Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 Spike for viral entry Taha Azad, Ragunath Singaravelu, Zaid Taha, Taylor R. Jamieson, Stephen Boulton, Mathieu J.F. Crupi, et al. (+18)
46 [GO] 2021―Feb―10 Vaccine technologies jockey for primacy in pandemic response Elie Dolgin
47 [GO] 2021―Feb―06 Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines S. Moein Moghimi
48 [GO] 2020―Dec―16 Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 Tesia Bobrowski, Lu Chen, Richard T. Eastman, Zina Itkin, Paul Shinn, Catherine Z. Chen, et al. (+7)
49 [GO] 2020―Oct―13 Prepandemic Preparedness under the Spotlight at ASGCT’s COVID-19 Symposium Elie Dolgin
50 [GO] 2020―Oct―09 The Road Less Traveled: SARS-CoV-2 and Cell-Mediated Immunity Kevin V. Morris
51 [GO] 2020―Oct―09 Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines Eric J. Kremer
52 [GO] 2020―Oct―08 COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing tissue migration molecule CD11a++ Moritz Anft, Krystallenia Paniskaki, Arturo Blazquez-Navarro, Adrian Doevelaar, Felix S. Seibert, Bodo Hölzer, et al. (+25)
53 [GO] 2020―Jun―23 Preparing for Pandemics: RNA Vaccines at the Forefront Jesse H. Erasmus, Deborah Heydenburg Fuller
54 [GO] 2020―Jun―12 The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2 Kevin V. Morris
55 [GO] 2020―Jun―10 Are genetic vaccines the right weapon against Covid-19? Antonella Conforti, Emanuele Marra, Giuseppe Roscilli, Fabio Palombo, Gennaro Ciliberto, Luigi Aurisicchio
 [1] 

55 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec